NCT05314738View on ClinicalTrials.gov

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

February 28, 2026

Conditions
Progressive Keratoconus
Interventions
COMBINATION_PRODUCT

NXL Energy 1

Riboflavin drops + NXL System to Total Energy Level 1

COMBINATION_PRODUCT

NXL Energy 2

Riboflavin drops + NXL System to Total Energy Level 2

COMBINATION_PRODUCT

NXL Energy 3

Riboflavin drops + NXL System to Total Energy Level 3

COMBINATION_PRODUCT

Sham Treatment

Sham Drops and No exposure to NXL system

Trial Locations (3)

36301

RECRUITING

Glaukos Investigative Site, Dothan

43082

RECRUITING

Glaukos Investigative Site, Westerville

07666

RECRUITING

Glaukos Investigative Site, Teaneck

Sponsors
All Listed Sponsors
lead

Glaukos Corporation

INDUSTRY

NCT05314738 - Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus | Biotech Hunter | Biotech Hunter